Fate Therapeutics, Inc. (FATE) short interest & options flow
NASDAQFATE enters the post-earnings session in an unusual position: a stock that rallied 81% over the past month is now being covered by shorts, not chased by them. Q1 results dropped this morning. EPS came in at -$0.26, beating the -$0.28 estimate. Revenue of $1.3M missed by roughly $0.25M — but for a clinical-stage iPSC therapy company still burning cash, the beat on the loss line…
FATE cost to borrow surges to 1.66% — up 192% in one week as short squeeze pressures mount.
- Market cap
- $212M
- Next earnings
- 13 Nov 2026
Key data as of 11 Nov 2026
Latest signals on FATE
- Cost to Borrow
FATE cost to borrow surges to 1.66% — up 192% in one week as short squeeze pressures mount.
FATE news and analysis
RSSNo long-form analysis yet for FATE. Pulse alerts and the live data picture are available on ORTEX.
Open FATE on ORTEX →Want the live picture for FATE?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for FATE — free to start on ORTEX.
Sign up for free →Open FATE on ORTEX